Wegovy and mental health: what the side-effect evidence actually shows

You've just started Wegovy and you feel… different. Not quite yourself.

It doesn't always announce itself dramatically. Sometimes it's a flatness that arrived a few weeks in, or a short temper that wasn't there before, or a quiet worry that you can't quite place. For some people starting Wegovy, mood shifts are the first thing they notice that isn't gastrointestinal.

The NHS medicines page for semaglutide does list mood-related effects in the prescribing information: anxiety, irritability, depression, and (in very rare cases) suicidal thoughts or thoughts of self-harm. These are not common. Across the clinical trials, serious psychiatric events were infrequent. But they are real enough that they deserve clear-eyed discussion rather than reassuring vagueness.

One useful habit: every few days, take sixty seconds to check in with yourself the same way you might track nausea or sleep. Just a mental note, am I lower, flatter, or more anxious than I was last week? Doing it consistently makes it much easier to spot a pattern rather than dismiss a feeling as a bad day.

Weight loss itself (and the significant appetite change that comes with it) can also affect mood independently of the medicine. Sleep improving, energy shifting, eating habits changing: all of these interact with how a person feels. That makes it genuinely difficult to attribute a mood change solely to Wegovy, which is one reason the regulatory picture is still evolving. See our fuller overview of Wegovy's broader health risks for context on how the prescribing community thinks about this.

What the regulators have actually found (and what remains uncertain

In 2023, the European Medicines Agency (EMA) and the MHRA launched a review specifically examining whether GLP-1 receptor agonists) including semaglutide, were linked to suicidal ideation and self-harm. The initial findings, published in 2024, did not confirm a causal relationship between these medicines and psychiatric events. Current evidence does not establish that semaglutide directly causes suicidal thinking in a way that goes beyond background rates in a population that is managing obesity.

That said, the authorities did not close the question entirely. Post-marketing surveillance is ongoing, and the side-effect listings in the UK SmPC retain the warnings. The EMA noted that the review was complicated by the fact that obesity and type 2 diabetes are themselves associated with higher rates of depression and anxiety, meaning disentangling medicine effects from underlying health profile is genuinely hard.

For a detailed look at how this compares across semaglutide formulations, the semaglutide mental side effects page covers the wider picture, including what Ozempic's prescribing history adds to the dataset. The short version: the evidence does not confirm harm, but monitoring matters, and individual responses vary enough that no blanket reassurance is appropriate.

When to get medical help, and what counts as urgent

There is a meaningful difference between feeling a bit flat after starting a new medicine and experiencing something that needs prompt attention. The following are the situations where waiting for your next check-in is the wrong call.

Contact a GP, call 111, or go to A&E if you develop thoughts of ending your life or harming yourself, even if they feel brief or distant. That is an emergency, not a side effect to manage at home. The same applies to any sudden, significant worsening of existing depression or anxiety, not a gradual mood dip but something that feels acute or frightening.

For less urgent but still concerning changes (persistent low mood over two weeks or more, new anxiety that is affecting sleep or daily functioning, or a noticeable shift in how you feel about yourself) contact the prescribing service or your GP for a review. Wegovy can usually be paused or the dose held while things are assessed; you do not have to push through.

If you are already under the care of a mental health team, tell them you are starting or have started Wegovy. GLP-1 medicines can interact with the emotional landscape of pre-existing conditions, and your mental health clinician should be part of the picture. There is more on navigating the broader Wegovy treatment journey on our main Wegovy page, including how our prescribers approach clinical review before and during treatment.

How Wegovy's mental health side-effect profile compares to its other effects (and what this means practically

Putting this in proportion: the most common Wegovy side effects are gastrointestinal) nausea, constipation, diarrhoea, affecting a substantial minority of users, particularly in the early weeks of treatment or after a dose step. Mood-related effects are considerably less common. The majority of people completing the STEP 1 trial did not report significant psychiatric events, and average weight loss of around 15% over 68 weeks was the headline finding from that research, published in the New England Journal of Medicine.

That context matters. It does not mean the psychiatric side effects are trivial, it means they affect a minority, and that minority deserves clear information rather than either alarmism or dismissal. Men may experience Wegovy's side effects differently in some respects, and that page covers what the evidence says by sex. Some people also notice physical changes they did not expect, and our page on Wegovy dental side effects is worth reading if you have picked up any changes to your teeth or gums since starting treatment.

If you are weighing up the full picture before starting treatment, our prescribers discuss psychiatric history, current mental health, and relevant medications as a routine part of the consultation. That conversation is free. It is also the most useful thing available to you before making a decision, and you can start your free consultation at any point.